Mark Sleeman
25Patents
11h-index
20Co-inventors
75Inventor score
Filing activity: Dec 3, 1999 → Apr 5, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8062640B2 | High affinity human antibodies to PCSK9 | Emerging Cross-Sectional Technologies | 126 | Active |
| US8357371B2 | Methods for treating hypercholesterolemia using antibodies to PCSK9 | Chemistry; Metallurgy | 75 | Active |
| US8501184B2 | High affinity human antibodies to PCSK9 | Emerging Cross-Sectional Technologies | 69 | Active |
| US7052691B2 | Methods of treating diabetes by blocking VEGF-mediated activity | Chemistry; Metallurgy | 28 | Expired |
| US8545847B2 | Human antibodies to the human glucagon receptor and methods of use thereof | Chemistry; Metallurgy | 25 | Active |
| US9018356B2 | Anti-ANGPTL3 antibodies and uses thereof | Chemistry; Metallurgy | 21 | Active |
| US7378095B2 | Methods of treating type I diabetes by blocking VEGF-mediated activity | Chemistry; Metallurgy | 20 | Expired |
| US9550837B2 | Therapeutic uses of anti-PCSK9 antibodies | Emerging Cross-Sectional Technologies | 19 | Active |
| US9127068B2 | Nucleic acids encoding human glucagon receptor antibodies | Chemistry; Metallurgy | 18 | Active |
| US10023654B2 | Anti-PCSK9 antibodies | Emerging Cross-Sectional Technologies | 11 | Active |
| US9724411B2 | Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9 | Chemistry; Metallurgy | 11 | Active |
| US9587029B2 | Human antibodies to the glucagon receptor and methods of use thereof | Chemistry; Metallurgy | 11 | Active |
| US9120851B2 | Human antibodies to human angiopoietin-like protein 4 | Chemistry; Metallurgy | 9 | Active |
| US8354103B2 | Human antibodies to human angiopoietin-like protein 4 | Chemistry; Metallurgy | 4 | Active |
| US10233250B2 | Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels | Chemistry; Metallurgy | 4 | Active |
| US10941210B2 | Anti-PCSK9 antibodies | Emerging Cross-Sectional Technologies | 4 | Active |
| US9951127B2 | Anti-ANGPTL3 antibodies and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US12250931B2 | Genetically modified mouse with a humanized PNPLA3 gene and methods of use | Chemistry; Metallurgy | 0 | Active |
| US10358487B2 | Anti-ANGPTL3 antibodies and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11780915B2 | Binding proteins to the human thrombin receptor, PAR4 | Chemistry; Metallurgy | 0 | Active |
| US11498970B2 | Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels | Chemistry; Metallurgy | 0 | Active |
| US10640566B2 | Nucleic acid molecules encoding antibodies to the human glucagon receptor | Chemistry; Metallurgy | 0 | Active |
| US6680291B1 | Modified ciliary neurotrophic factor, method of making and methods of use thereof | Human Necessities | 0 | Expired |
| US12269897B2 | Anti-PCSK9 antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US12269889B2 | Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.